Literature DB >> 12417250

Nociceptin/orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection.

C Le Cudennec1, B Naudin, J-C Do Rego, J Costentin.   

Abstract

Nociceptin/orphanin FQ (=N/OFQ), the endogenous ligand of ORL1 receptor (=NOP), has been reported to induce, in rodents, after intracerebroventricular (i.c.v.) administration, anti-stress and anxiolytic effects. We have observed that the handling of mice followed by an i.c.v. injection of saline, induced a marked increase in the plasma corticosterone level (+250%) measured 30 minutes later. When N/OFQ was injected intracerebroventricularly, using a 1 microg dose, the increase in plasma corticosterone was significantly lower than in saline injected mice. N/OFQ(1-13)NH(2), known as a NOP receptor agonist, at the same 1 microg dose, also induced a lesser increase in plasma corticosterone level than a saline i.c.v. injection. The pseudopeptide [Phe(1)-psi(CH(2)-NH)Gly(2)]N/OFQ(1-13)NH(2), defined either as an agonist or an antagonist of NOP receptor, at the 0.1 microg dose, behaved in a similar manner as N/OFQ, by decreasing the plasma corticosterone level. Finally, [Nphe(1)]N/OFQ(1-13)NH(2), although presumed to be a selective NOP receptor antagonist, also decreased the corticosterone level at the 0.1 microg dose. These observations suggest the implication of N/OFQ in the regulation of response to stress, through an action on the hypothalamo-pituitary-adrenocortical axis. Moreover, they evidence a similar effect of N/OFQ and N/OFQ(1-13)NH(2), but also of two other related peptides displaying antagonist properties on NOP receptors. These data suggest that several subtypes of N/OFQ receptors could exist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417250     DOI: 10.1016/s0024-3205(02)02218-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice.

Authors:  Maarten van den Buuse; Margaret Morris; Carolina Chavez; Sally Martin; JianHong Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

2.  Behavioral effects of urotensin-II centrally administered in mice.

Authors:  Jean-Claude Do-Rego; David Chatenet; Marie-Hélène Orta; Bertrand Naudin; Camille Le Cudennec; Jérôme Leprince; Elizabeth Scalbert; Hubert Vaudry; Jean Costentin
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

3.  Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression.

Authors:  Malika El Yacoubi; Saoussen Bouali; Daniela Popa; Laurent Naudon; Isabelle Leroux-Nicollet; Michel Hamon; Jean Costentin; Joëlle Adrien; Jean-Marie Vaugeois
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

4.  Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Authors:  Steven D Chang; Lawrence E Brieaddy; Joseph D Harvey; Anita H Lewin; S Wayne Mascarella; Herbert H Seltzman; P Anantha Reddy; Ann M Decker; Charles J McElhinny; Desong Zhong; Elisha E Peterson; Hernán A Navarro; Michael R Bruchas; F Ivy Carroll
Journal:  ACS Chem Neurosci       Date:  2015-09-30       Impact factor: 4.418

Review 5.  Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists.

Authors:  Jong Yung Park; Suji Chae; Chang Seop Kim; Yoon Jae Kim; Hyun Joo Yi; Eunjoo Han; Youngshin Joo; Surim Hong; Jae Won Yun; Hyojung Kim; Kyung Ho Shin
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

Review 6.  A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia.

Authors:  Muhammad Saad Khan; Isabelle Boileau; Nathan Kolla; Romina Mizrahi
Journal:  Transl Psychiatry       Date:  2018-02-02       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.